血小板糖蛋白(GP)Ⅱb/Ⅲa受体抑制剂能降低冠脉介入术后缺血性卒中并发率。然而关于75岁以上老人接受经皮冠脉介入治疗期间辅用 GPⅡb/Ⅲa 受体抑制剂相关药效及其安全性尚未清楚,本文就此与75岁以下者进行了对照分析。对象与方法 1369例接受经皮冠脉支架植入术者,其中75岁以上老人240例,余1129例为75岁以下者。部分对象于术中辅用了 GPⅡb/Ⅲa 受体抑制剂,前者多选用 Tirofiban,后者多选用 Eptifibatide。所有对象均于术前24h 启用术后连 Platelet glycoprotein (GP) IIb / IIIa receptor inhibitors can reduce the incidence of ischemic stroke after coronary intervention. However, the efficacy and safety of GPⅡb / Ⅲa receptor inhibitors supplemented with percutaneous coronary intervention during the percutaneous coronary intervention are still unclear. This article was compared with those under 75 years of age. Subjects and Methods 1369 patients undergoing percutaneous coronary stenting were enrolled, of whom 240 were elderly 75 years and over 1129 were under 75 years of age. Part of the object in the surgery assisted with GP Ⅱ b / Ⅲ a receptor inhibitors, the former use more Tirofiban, the latter use more Eptifibatide. All subjects were enrolled after operation 24h before surgery